Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure (HF) hospitalizations and cardiovascular mortality among patients with HF and left ventricular ejection fraction (LVEF) ≤40%. There is emerging evidence of the benefits of SGLT2i in HF patients with a higher LVEF (>40%). We aimed to evaluate the benefits of SGLT2i in different subgroups [...]

Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure (HF) hospitalizations and cardiovascular mortality among patients with HF and left ventricular ejection fraction (LVEF) ≤40%. There is emerging evidence of the benefits of SGLT2i in HF patients with a higher LVEF (>40%). We aimed to evaluate the benefits of SGLT2i in different subgroups [...]

Background: Treating HFpEF (heart failure with preserved ejection fraction) is complex due to its diverse origins, leaving many patients with limited options. While diuretics offer symptom relief, most therapies don’t markedly improve outcomes. SGLT2 inhibitors, particularly Dapagliflozin, show potential in reducing cardiovascular events. Yet, guidelines for HFpEF and HFmrEF are vague regarding SGLT2 use. This [...]

Background: The diagnosis of sepsis is often associated with high rates of morbidity and mortality. When it occurs in patients with Heart failure (HF), those rates increase dramatically. This study focuses on the differences in the outcomes in septic patients with Heart Failure with preserved Ejection Fraction (HFpEF) versus patients with Heart Failure with reduced [...]

Background: The key goals of HF therapy are to prevent progression of symptoms, improve quality of life, and prolong survival. Studies have attempted to study and improve post hospitalization outcomes among patients with HF. Social determinants of Health include a wide set of factors from daily life which are responsible for health inequity. Burden of [...]

Background: Heart failure (HF) and atrial fibrillation (AF) share several risk factors including coronary artery disease, hypertension, smoking, obesity, diabetes, and renal disease, as well as common pathophysiologic pathway involving activation of the renin–angiotensin–aldosterone system, maladaptive atrial remodeling and subsequent impaired conduction system. Some studies have supported the role of angiotensin converting enzyme inhibitors (ACEIs) [...]

Case Presentation: A 58-year-old female with hypertension and end stage renal disease (ESRD) on hemodialysis was admitted with subacute dyspnea accompanied by abdominal pain and swelling. During a previous admission for similar symptoms three months prior, CT of the abdomen and pelvis revealed ascites and an adnexal mass measuring 8.6×5.2 cm. She was treated for [...]